Press releaseACCESS Newswire
CV Sciences
CVSI · OTC
$0.01−$0.0012 (−10.71%)TodayMarket closed ·
Prev close $0.0112
Latest news
- News
CV Sciences Q2 2026 Earnings Call Transcript
- News
CV Sciences Q2 Adj. EPS $0.00, Sales $2.985M Down From $3.620M YoY
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026
- News
CV Sciences Reports Q1 2026 Results: Full Earnings Call Transcript
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports Third Quarter 2025 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports Second Quarter 2025 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. To Announce Second Quarter 2025 Results On August 13, 2025
- Press releaseACCESS Newswire
CV Sciences, Inc. Applauds Governor Abbot's Veto of Senate Bill 3
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports First Quarter 2025 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. to Announce First Quarter 2025 Results on May 14, 2025
- Press releaseACCESS Newswire
CV Sciences, Inc. Reports Fiscal Year-End 2024 Financial Results
- Press releaseACCESS Newswire
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025
- NewsJelena Martinovic
Hemp-Focused CV Sciences Expands Via New Cannabis Acquisition, Here's What Investors Need To Know
- Press releasePRNewswire
CV Sciences, Inc. Enters Into Definitive Agreement to Acquire Extract Labs
- NewsPatricio Liddle
CV Sciences Q3: Revenue Stable Amid New Launches, Financing
- Press releasePRNewswire
CV Sciences, Inc. Reports Third Quarter 2024 Financial Results
- Press releasePRNewswire
CV Sciences, Inc. To Announce Third Quarter 2024 Results On November 14, 2024
- Press releasePRNewswire
CV Sciences Launches +PlusHLTH, a New Line of Cannabinoid-Free Supplements
- NewsJelena Martinovic
Hemp-Focused CV Sciences Reports Flat Revenue And Over 8% YoY Increase In Gross Profit In Q2
- Press releasePRNewswire
CV Sciences, Inc. Reports Second Quarter 2024 Financial Results
- Press releasePRNewswire
CV Sciences, Inc. To Announce Second Quarter 2024 Results On August 13, 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.